A certain drug is used to treat asthma. In a clinical trial of the?drug, 15 of 250 treated subjects experienced headaches?(based on data from the?manufacturer). The accompanying calculator display shows results from a test of the claim that less than 10?% of treated subjects experienced headaches. Use the normal distribution as an approximation to the binomial distribution and assume a 0.01 significance level to complete parts?(a) through?(e) below.

A certain drug is used to treat asthma. In a clinical trial of the drug, 15 of 250 treated subjects experienced headaches (based on data from the manufacturer). The accompanying calculator display shows results from a test of the claim that less than 10% of treated subjects experienced headaches. Use the normal distribution as an approximation to the binomial distribution and assume a 0.01 signicance level to complete parts (a) through (e) below. a. Is the test two-tailed, left-tailed, or righttailed? O Left-tailed test O Two-tailed test 0 Right tailed test b. What is the test statistic? z = (Round to two decimal places as needed.) c. What is the P-value? P-value = (Round to four decimal places as needed.) 1-PropZTest prop 0.1 O C. Ho: P = 0.1 OD. Ho: p #0.1 Decide whether to reject the null hypothesis. Choose the correct answer below. O A. Fail to reject the null hypothesis because the P-value is greater than the significance level, a. O B. Reject the null hypothesis because the P-value is greater than the significance level, a. O C. Reject the null hypothesis because the P-value is less than or equal to the significance level, a. O D. Fail to reject the null hypothesis because the P-value is less than or equal to the significance level, a.e. What is the final conclusion? O A. There is sufficient evidence to support the claim that less than 10% of treated subjects experienced headaches. O B. There is sufficient evidence to warrant rejection of the claim that less than 10% of treated subjects experienced headaches. O C. There is not sufficient evidence to warrant rejection of the claim that less than 10% of treated subjects experienced headaches. O D. There is not sufficient evidence to support the claim that less than 10% of treated subjects experienced headaches